CN Bio Innovations, an expert in developing human biomimetic platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with RNA based drug discovery and development company Isis Pharmaceuticals Inc.
Research relevant to Isis’s innovative RNA targeting, antisense oligonucleotides will be performed at CN Bio’s facility in Welwyn Garden City, UK and take advantage CN Bio’s proprietary LiverChip® 3D perfused culture platform. This research seeks to determine the feasibility of using CN Bio’s high integrity models for rapid and accurate in vitro testing of Isis’ anti-viral drug candidates.
About Isis Pharmaceuticals, Inc.
Isis is exploiting its leadership position in RNA-targeted technology to discover and develop novel drugs for its product pipeline and for its partners. Isis’ broad pipeline consists of 38 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis has numerous drugs in Phase 3 development in severe/rare diseases and cardiovascular diseases. Isis’ patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.
About CN Bio Innovations
CN Bio Innovations is part of Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio provides human biomimetic platforms for the testing and development of therapeutics for serious human diseases, including Hepatitis B and C. Working closely with academic pioneers in the bio-engineering field, CN Bio is developing next generation tissue and disease models which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market. Additional information about CN Bio is available at www.cn-bio.com.